-
Je něco špatně v tomto záznamu ?
Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial
M. Suttorp, P. Schulze, I. Glauche, G. Göhring, N. von Neuhoff, M. Metzler, P. Sedlacek, ESJM. de Bont, A. Balduzzi, B. Lausen, O. Aleinikova, S. Sufliarska, G. Henze, G. Strauss, A. Eggert, B. Kremens, AH. Groll, F. Berthold, C. Klein, U....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu klinické zkoušky, fáze III, časopisecké články, práce podpořená grantem
NLK
ProQuest Central
od 1997-02-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Nursing & Allied Health Database (ProQuest)
od 1997-02-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-02-01 do Před 1 rokem
- MeSH
- biologické markery MeSH
- chronická myeloidní leukemie farmakoterapie mortalita patologie MeSH
- dítě MeSH
- imatinib mesylát aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- inhibitory proteinkinas aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- kojenec MeSH
- kombinovaná terapie MeSH
- kostní dřeň patologie MeSH
- lidé MeSH
- mladiství MeSH
- neúspěšná terapie MeSH
- předškolní dítě MeSH
- prognóza MeSH
- progrese nemoci MeSH
- protinádorové látky aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- staging nádorů MeSH
- stupeň nádoru MeSH
- výsledek terapie MeSH
- Check Tag
- dítě MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- práce podpořená grantem MeSH
A total of 156 patients (age range 1.3-18.0 years, median 13.2 years; 91 (58.3%) male) with newly diagnosed CML (N = 146 chronic phase (CML-CP), N = 3 accelerated phase (CML-AP), N = 7 blastic phase (CML-BP)) received imatinib up-front (300, 400, 500 mg/m2, respectively) within a prospective phase III trial. Therapy response, progression-free survival, causes of treatment failure, and side effects were analyzed in 148 children and adolescents with complete data. Event-free survival rate by 18 months for patients in CML-CP (median follow-up time 25 months, range: 1-120) was 97% (95% CI, 94.2-99.9%). According to the 2006 ELN-criteria complete hematologic response by month 3, complete cytogenetic response (CCyR) by month 12, and major molecular response (MMR) by month 18 were achieved in 98, 63, and 59% of the patients, respectively. By month 36, 86% of the patients achieved CCyR and 74% achieved MMR. Thirty-eight patients (27%) experienced imatinib failure because of unsatisfactory response or intolerance (N = 9). In all, 28/148 patients (19%) underwent stem cell transplantation (SCT). In the SCT sub-cohort 2/23 patients diagnosed in CML-CP, 0/1 in CML-AP, and 2/4 in CML-BP, respectively, died of relapse (N = 3) or SCT-related complications (N = 2). This large pediatric trial extends and confirms data from smaller series that first-line imatinib in children is highly effective.
Belarus Research Center for Pediatric Oncology Hematology and Immunology Minsk Belarus
Department of Human Genetics Hannover Medical School Hannover Germany
Department of Pediatrics 3 University Hospital University of Duisburg Essen Duisberg Germany
Department of Pediatrics BMT Unit Comenius University Children's Hospital Bratislava Slovakia
Institute of Pathology Hannover Medical School Hannover Germany
Medical Department 1 University Hospital Carl Gustav Carus TU Dresden Dresden Germany
Paediatric Hematology and Oncology Hannover Medical School Hannover Germany
Pediatric Hematology and Oncology University Children's Hospital Charité Berlin Germany
Pediatric Hematology and Oncology University Children's Hospital Cologne Germany
Pediatric Hematology and Oncology University Children's Hospital Erlangen Germany
Pediatric Hematology and Oncology University Children's Hospital Kiel Germany
Pediatric Hematology and Oncology University Children's Hospital Münster Germany
Pediatric Oncology Hematology and Immunology University Children's Hospital Heidelberg Germany
University Children's Hospital Ludwig Maximilians University Munich Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19028365
- 003
- CZ-PrNML
- 005
- 20190815105432.0
- 007
- ta
- 008
- 190813s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41375-018-0179-9 $2 doi
- 035 __
- $a (PubMed)29925908
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Suttorp, Meinolf $u Pediatric Hematology and Oncology, Department of Pediatrics, University Hospital "Carl Gustav Carus", TU Dresden, Dresden, Germany. meinolf.suttorp@uniklinikum-dresden.de.
- 245 10
- $a Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial / $c M. Suttorp, P. Schulze, I. Glauche, G. Göhring, N. von Neuhoff, M. Metzler, P. Sedlacek, ESJM. de Bont, A. Balduzzi, B. Lausen, O. Aleinikova, S. Sufliarska, G. Henze, G. Strauss, A. Eggert, B. Kremens, AH. Groll, F. Berthold, C. Klein, U. Groß-Wieltsch, KW. Sykora, A. Borkhardt, AE. Kulozik, M. Schrappe, C. Nowasz, M. Krumbholz, JT. Tauer, A. Claviez, J. Harbott, HH. Kreipe, B. Schlegelberger, C. Thiede,
- 520 9_
- $a A total of 156 patients (age range 1.3-18.0 years, median 13.2 years; 91 (58.3%) male) with newly diagnosed CML (N = 146 chronic phase (CML-CP), N = 3 accelerated phase (CML-AP), N = 7 blastic phase (CML-BP)) received imatinib up-front (300, 400, 500 mg/m2, respectively) within a prospective phase III trial. Therapy response, progression-free survival, causes of treatment failure, and side effects were analyzed in 148 children and adolescents with complete data. Event-free survival rate by 18 months for patients in CML-CP (median follow-up time 25 months, range: 1-120) was 97% (95% CI, 94.2-99.9%). According to the 2006 ELN-criteria complete hematologic response by month 3, complete cytogenetic response (CCyR) by month 12, and major molecular response (MMR) by month 18 were achieved in 98, 63, and 59% of the patients, respectively. By month 36, 86% of the patients achieved CCyR and 74% achieved MMR. Thirty-eight patients (27%) experienced imatinib failure because of unsatisfactory response or intolerance (N = 9). In all, 28/148 patients (19%) underwent stem cell transplantation (SCT). In the SCT sub-cohort 2/23 patients diagnosed in CML-CP, 0/1 in CML-AP, and 2/4 in CML-BP, respectively, died of relapse (N = 3) or SCT-related complications (N = 2). This large pediatric trial extends and confirms data from smaller series that first-line imatinib in children is highly effective.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a protinádorové látky $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000970
- 650 _2
- $a biologické markery $7 D015415
- 650 _2
- $a kostní dřeň $x patologie $7 D001853
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imatinib mesylát $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000068877
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a chronická myeloidní leukemie $x farmakoterapie $x mortalita $x patologie $7 D015464
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a stupeň nádoru $7 D060787
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a inhibitory proteinkinas $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D047428
- 650 _2
- $a neúspěšná terapie $7 D017211
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Schulze, Philipp $u Institute for Medical Informatics and Biometry, Faculty of Medicine "Carl Gustav Carus", TU Dresden, Dresden, Germany.
- 700 1_
- $a Glauche, Ingmar $u Institute for Medical Informatics and Biometry, Faculty of Medicine "Carl Gustav Carus", TU Dresden, Dresden, Germany.
- 700 1_
- $a Göhring, Gudrun $u Department of Human Genetics, Hannover Medical School, Hannover, Germany.
- 700 1_
- $a von Neuhoff, Nils $u Department of Human Genetics, Hannover Medical School, Hannover, Germany. Department of Pediatrics III, University Hospital, University of Duisburg-Essen, Duisberg, Germany.
- 700 1_
- $a Metzler, Markus $u Pediatric Hematology and Oncology, University Children's Hospital, Erlangen, Germany.
- 700 1_
- $a Sedlacek, Petr $u Pediatric Hematology and Oncology, Teaching Hospital Motol, 2nd Medical School, Charles University Motol, Prague, Czech Republic.
- 700 1_
- $a de Bont, Eveline S J M $u Pediatric Hematology and Oncology, University Children's Hospital, Groningen, The Netherlands. Dutch Childhood Oncology Group (DCOG), The Hague, The Netherlands.
- 700 1_
- $a Balduzzi, Adriana $u Pediatric Hematology and Hematopoietic Stem Cell Transplantation Unit, Clinica Pediatrica Università degli Studi di Milano Bicocca, Ospedale San Gerardo, Monza, Italy.
- 700 1_
- $a Lausen, Birgitte $u Department of Pediatric and Adolescent Medicine, University Hospital, Rigshospitalet, Copenhagen, Denmark.
- 700 1_
- $a Aleinikova, Olga $u Belarus Research Center for Pediatric Oncology, Hematology, and Immunology, Minsk, Belarus.
- 700 1_
- $a Sufliarska, Sabina $u Department of Pediatrics, BMT Unit, Comenius University Children's Hospital, Bratislava, Slovakia.
- 700 1_
- $a Henze, Günter $u Pediatric Hematology and Oncology, University Children's Hospital, Charité Berlin, Germany.
- 700 1_
- $a Strauss, Gabriele $u Pediatric Hematology and Oncology, University Children's Hospital, Charité Berlin, Germany. Pediatric Hematology and Oncology, Helios KlinikenBerlin-Buch, Berlin, Germany.
- 700 1_
- $a Eggert, Angelika $u Pediatric Hematology and Oncology, University Children's Hospital, Charité Berlin, Germany.
- 700 1_
- $a Kremens, Bernhard $u Department of Pediatrics III, University Hospital, University of Duisburg-Essen, Duisberg, Germany.
- 700 1_
- $a Groll, Andreas H $u Pediatric Hematology and Oncology, University Children's Hospital, Münster, Germany.
- 700 1_
- $a Berthold, Frank $u Pediatric Hematology and Oncology, University Children's Hospital, Cologne, Germany.
- 700 1_
- $a Klein, Christoph $u University Children's Hospital, Ludwig Maximilians University, Munich, Germany.
- 700 1_
- $a Groß-Wieltsch, Ute $u Pediatric Oncology, Hematology, Immunology, Stuttgart Cancer Center, Klinikum Stuttgart-Olgahospital, Stuttgart, Germany.
- 700 1_
- $a Sykora, Karl Walter $u Paediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
- 700 1_
- $a Borkhardt, Arndt $u Pediatric Hematology, Oncology, and Clinical Immunology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
- 700 1_
- $a Kulozik, Andreas E $u Pediatric Oncology, Hematology, and Immunology, University Children's Hospital, Heidelberg, Germany.
- 700 1_
- $a Schrappe, Martin $u Pediatric Hematology and Oncology, University Children's Hospital, Kiel, Germany.
- 700 1_
- $a Nowasz, Christina $u Pediatric Hematology and Oncology, Department of Pediatrics, University Hospital "Carl Gustav Carus", TU Dresden, Dresden, Germany.
- 700 1_
- $a Krumbholz, Manuela $u Pediatric Hematology and Oncology, University Children's Hospital, Erlangen, Germany.
- 700 1_
- $a Tauer, Josephine T $u Pediatric Hematology and Oncology, Department of Pediatrics, University Hospital "Carl Gustav Carus", TU Dresden, Dresden, Germany. Shriners Hospitals for Children, Montréal, Canada.
- 700 1_
- $a Claviez, Alexander $u Pediatric Hematology and Oncology, University Children's Hospital, Kiel, Germany.
- 700 1_
- $a Harbott, Jochen $u Oncogenetic Laboratory, Pediatric Hematology and Oncology, University Children's Hospital, Giessen, Germany.
- 700 1_
- $a Kreipe, Hans H $u Institute of Pathology, Hannover Medical School, Hannover, Germany.
- 700 1_
- $a Schlegelberger, Brigitte $u Department of Human Genetics, Hannover Medical School, Hannover, Germany.
- 700 1_
- $a Thiede, Christian $u Medical Department I, University Hospital "Carl Gustav Carus", TU Dresden, Dresden, Germany.
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 32, č. 7 (2018), s. 1657-1669
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29925908 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190815105700 $b ABA008
- 999 __
- $a ok $b bmc $g 1433514 $s 1066825
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 32 $c 7 $d 1657-1669 $e 20180620 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- LZP __
- $a Pubmed-20190813
